Results from Clinical Trial of Tagraxofusp in Patients with Intermediate or High Risk R/R MF

Results from Phase 1/2 Clinical Trial of Tagraxofusp (SL-401) in Patients with Intermediate or High Risk Relapsed/Refractory Myelofibrosis. ASH 2019.